Brown adipose tissue activation on PET-CT in patients diagnosed with pheochromocytomas or Cushings syndrome.

Brown adipose tissue activation on PET-CT in patients diagnosed with pheochromocytomas or Cushings syndrome. - Hormonal activation of BAT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37498

Enrollment

Registered

2013-06-10

Start date

2013-07-22

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome obesity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Documented diagnosis of pheochromocytoma or cushing syndrome -Signed informed consent -3 months stable medication, described for other comorbidities, -Female or Male subjects of 18 years or older

Exclusion criteria

Exclusion criteria: -BMI>35 -Use of a PPAR-γ agonist -Use of insulin -If female, pregnancy or breast feeding -Drug or alcohol dependence or abuse -Participation in a trial of an experimental drug or device within 60 days prior to screening for pheochromocytoma or Cushing syndrome.

Design outcomes

Primary

Measure	Time frame
BAT activity measured by FDG-PET.	—

Secondary

Measure	Time frame
- Insulin sensitivity measured by a modified insulin tolerance test - Study body composition before and after treatment, measured by DXA scan - Tissue analysis of perirenal BAT obtained during adrenalectomy. - Study serum BAT activity markers.	—

Countries

Netherlands

Outcome results